OnKure Therapeutics, Inc. — Director's Dealing 2021

Apr 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Reneo Pharmaceuticals, Inc. (RPHM)
CIK: 0001637715
Period of Report: 2021-04-13

Reporting Person: Muralidhar Bali (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-13	Common Stock	C	1658226	—	Acquired	1658226	Indirect
2021-04-13	Common Stock	P	200000	$15.00	Acquired	1858226	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-13	Series B Preferred Stock	$	C	7420232	Disposed		Common Stock (1658226)	Indirect

Footnotes

F1: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date.

F2: See Exhibit 99.1

F3: The shares were purchased in the Issuer's initial public offering.